Research programme: PEP compounds - Peplin Limited

Drug Profile

Research programme: PEP compounds - Peplin Limited

Alternative Names: PEP 006; PEP 008; PEP 010

Latest Information Update: 18 Jan 2010

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Class Macrocyclic compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Actinic keratosis; Basal cell cancer; Squamous cell cancer

Most Recent Events

  • 18 Jan 2010 Discontinued - Preclinical for Actinic keratosis in USA (Intralesional)
  • 18 Jan 2010 Discontinued - Preclinical for Basal cell cancer in USA (Topical)
  • 18 Jan 2010 Discontinued - Preclinical for Squamous cell cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top